Type 2 Diabetes Remission: What Is Behind the 54% Result in a New Trial

27 of 50 participants in an intensive program achieved type 2 diabetes remission, compared with two of 46 controls. These are results from RESET for Remission, reported by the European Association for the Study of Diabetes, EASD, on September 30, 2026. The study appeared in The Lancet Regional Health - Americas.

The number attracts attention, but its meaning depends on details: who entered, what support they received, and what counted as remission. Without these, the finding can easily be read as a personal promise it does not provide.

Who the program was designed for

The protocol published in BMJ Open, targeted people aged 18 to 45 with obesity, diagnosed with type 2 diabetes within the past six years and not receiving insulin. It was tested at centers in England and Canada, not in an Israeli population.

This distinction matters to readers wondering whether the news applies to them. The study does not address type 1 diabetes, and its success rate cannot be transferred to older people, insulin users, or those living longer with diabetes. Suitability starts with a medical assessment, not matching a headline.

A treatment framework stood behind the diet

The intensive phase was planned for 12 weeks and combined a low-energy diet based on meal replacements, later including regular food. The base was about 800 to 900 calories daily, adjusted for exercise days. Training included supervised aerobic activity and strength exercises alongside independent activity. A 12-week phase maintaining weight and activity followed.

The protocol included professionals, monitoring, and medication adjustments. These were part of the tested intervention. Similar food restriction without that framework does not replicate the study. Its calorie figure describes research treatment, not a dietary target for readers.

What remission means, and what remains under follow-up

The study defined remission as HbA1c below 6.5% at 24 weeks, without glucose-lowering medication during the preceding 12 weeks. HbA1c, glycated hemoglobin, assesses blood sugar control over time.

The concept follows the international consensus principle on diabetes remission: glucose values below the diagnostic threshold without glucose-lowering medication for the required period. Remission is not a permanent cure or erasure of the diagnosis. Blood sugar may rise again.

Monitoring of HbA1c and possible complications therefore continues. The consensus emphasizes eye examinations, kidney function, feet, and blood pressure alongside metabolic follow-up. One good test result is no reason to cancel appointments or skip routine checks.

A promising result, but the long-term question remains

The trial randomized 96 participants, and 86 reached the final assessment. According to EASD, no serious adverse events were reported, but 43 of 50 intervention participants experienced at least one adverse event, versus six controls. Early reported effects included constipation, headaches, dizziness, and fatigue.

A 24-week follow-up does not show how many will remain in remission in two or five years. The program combined nutrition and exercise, so the full result cannot be attributed to either alone. Long-term benefits and the feasibility of a similar framework outside research still require investigation.

What to bring to your next clinic appointment

For people with type 2 diabetes interested in remission, the study offers a discussion with their family doctor or diabetes clinic: whether a supervised program suits them, who will guide nutrition and exercise, and how follow-up will be arranged.

Do not stop medications or begin severe calorie restriction independently. The useful question is which personal program can be followed safely and sustained after the intensive phase. For more on everyday eating habits, see hidden sugar after the holidays.